Signal Ledger valuation · XOM
ExxonMobil Holdings Corp
What the shares are worth today on our research (cited consensus, company plans and peers, since management sets no usable targets): every line valued at the end of FY2030, net debt rolled forward, then discounted back to Jun 30, 2026.
- Business value at FY2030
- $741B
- FY2030 revenue
- $372B
- FY2030 EPS · P/E
- $11.00 · 18×
- Discount rate (WACC · equity)
- 7.54% · 7.87%
How this is built. The updated corporate plan supplies production, unit earnings and constant-price cash-flow goals but no segment revenue targets. FY2030 matched gross revenue and EBIT are derived at the plan mid-cycle price; internal transfers are explicitly eliminated. Price, mix and affiliate-cash allocations remain research estimates. Each input below shows its basis: consensus, company plan, peer or rule.
What each business is worth
| Business | Model | FY2030 revenue | Value today | Per share | 2030 multiple | Value from beyond FY2030 |
|---|---|---|---|---|---|---|
| Upstream | Margin | $136B | $578B | $140.62 | 15.1× EBIT | 61% |
| Energy Products | Margin | $318B | $134B | $32.67 | 10.4× EBIT | 53% |
| Chemical Products | Margin | $37B | $25B | $6.09 | 32.0× EBIT | 61% |
| Specialty Products | Margin | $23B | $47B | $11.53 | 11.0× EBIT | 61% |
| Company costsHead-office costs no segment carries, valued as one negative business | Cost line | — | −$75B | −$18.25 | — | 61% |
| All businesses | $372B | $710B | $172.66 |
From 2030 back to today
- Enterprise value at end of FY2030$741B
- Plus net cash at FY2030$93B
- Equity value at FY2030$834B
- ÷ (1 + 7.87%)^4.5 years at the cost of equity$593B
- + dividends paid on the way, discounted$64B
This reconciliation checks the published Signal Ledger valuation against the net-debt path. The difference is 2.1%, inside our 5% tolerance.
From businesses to one share
- All businesses, valued today$710B
- − borrowings$42B
- − finance leases$0B
- − preferred and minority claims$6.7B
- + cash and short-term investments$11B
- ÷ diluted shares4.112B
- Signal Ledger valuation$163.30
Year by year to FY2030
| Fiscal year | Revenue | EBITDA | Capex | Free cash flow | Net debt at year end |
|---|---|---|---|---|---|
| FY2026 | $474B | $80B | $28B | $46B | $24B |
| FY2027 | $446B | $81B | $29B | $46B | $4.1B cash |
| FY2028 | $419B | $82B | $29B | $46B | $33B cash |
| FY2029 | $395B | $83B | $30B | $46B | $63B cash |
| FY2030 | $372B | $84B | $31B | $46B | $93B cash |
What must be true
- Upstream holds revenue roughly flat, from $137.0B in FY2026 to $135.7B in FY2030.
- Energy Products revenue shrinks from $436.3B in FY2026 to $318.1B in FY2030 (-27.1%).
- Chemical Products revenue shrinks from $39.8B in FY2026 to $37.3B in FY2030 (-6.3%).
- Specialty Products holds revenue roughly flat, from $23.8B in FY2026 to $23.1B in FY2030.
- Upstream raises its EBIT margin from 25.7% to 30.1%.
- Energy Products raises its EBIT margin from 3.3% to 3.8%.
- Chemical Products raises its EBIT margin from 0.2% to 2.2%.
- Specialty Products raises its EBIT margin from 17.7% to 19.7%.
- The company spends $146.2B of capital expenditure through FY2030.
- Net debt peaks at $38.5B in FY2025 and stays financeable.
What the price implies
To reach $178.23 at our discount rate, ExxonMobil Holdings Corp would need about $573.5B of FY2030 sales (a decline of about 2.6% a year from FY2026) with 11.4% GAAP EBIT margin — versus $514.3B and 11.4% GAAP EBIT margin in our research.
At the research price of $178.23 (2026-10-23), the price asks more than our assumptions overall. These are operating requirements at that price, not additional valuations or forecasts.
If sales and margins changed together
Each row matches the same research price at our unchanged discount rate, by scaling every operating line's margin by one common factor. Sales cover margin and capacity lines only; other valuation lines stay fixed. Margins are revenue-weighted within each metric, before separately modeled corporate costs and eliminations. The conclusion uses the row at our research margins when sales alone can match the price, otherwise the solved row needing the least sales growth; this is a trade-off between growth and profitability, not a forecast.
| FY2030 sales factor | FY2030 sales | FY2026–30 CAGR | Required FY2030 margin | Requirement |
|---|---|---|---|---|
| 1.12×At research margins | $573.5B | −2.6% | 11.4% GAAP EBIT | Within margin guardrails |
| 1.50× | $771.5B | 4.9% | 8.9% GAAP EBIT | Within margin guardrails |
| 2.00× | $1,028.7B | 12.7% | 7.0% GAAP EBIT | Within margin guardrails |
| 3.00× | $1,543B | 24.8% | 5.0% GAAP EBIT | Within margin guardrails |
CAGR uses $637B of same-scope FY2026 sales from the published model or its sourced research base, over four fiscal years. “Within margin guardrails” checks numeric limits only, not commercial plausibility. Each line and year must stay at or below 50.0% GAAP EBIT and 100% EBITDA, or our research margin where that is higher; capacity EBIT uses the engine's equipment depreciation. Unsolved margins are not extrapolated.
- Implied discount rate
- 7.1%
- All-business FY2030 sales factor
- 1.12×
The WACC that makes model value equal the price, shifting WACC and cost of equity by the same amount. Model: 7.5% WACC · 7.9% cost of equity.
FY2030 revenue would need to reach $573.5B (model: $514.3B) across the margin and capacity businesses. FY1 stays fixed; the sales change ramps to FY2030 and stays at that factor thereafter.
If only one business changed
Businesses with margin or capacity revenue paths, ordered by value today. Revenue and margin are separate alternatives; these requirements are not added together.
Upstream
- Revenue alone
- FY2030 revenue would need to reach $154.1B (model: $135.7B).
- Margin alone
FY2030 EBIT margin would need to reach 34.0% (model: 30.1%).
Energy Products
- Revenue alone
- FY2030 revenue would need to reach $557.1B (model: $318.1B).
- Margin alone
FY2030 EBIT margin would need to reach 5.8% (model: 3.8%).
Specialty Products
- Revenue alone
- FY2030 revenue would need to reach $56B (model: $23.1B).
- Margin alone
FY2030 EBIT margin would need to reach 43.0% (model: 19.7%).
Chemical Products
- Revenue alone
- This business alone cannot get there within the search range.
- Margin alone
- This business alone cannot get there within the search range.
Mechanical requirements, not forecasts. The separate sales-only and single-business factors are searched from 0.1× to 6×; an unsolved comparison means this business alone cannot get there within those bounds. Single-business revenue changes apply from FY2 onward; margin changes scale the full EBIT or EBITDA margin path. Mixed groups show revenue-weighted EBIT and EBITDA margins separately. Requirements above 100% are not feasible margins. Joint rows instead search non-negative uniform margin factors only up to the EBIT/EBITDA guardrails; the entire margin path scales, including post-FY2030 convergence. Sales and margins change together only in that table. The rate search runs from the largest terminal growth rate plus 0.5 percentage points to 30% WACC.
The discount rate
- Cost of equity
- 7.87%
- WACC
- 7.54%
- 10-year Treasury · model / spot
- 3.87% · 5.13%
r_f 3.87% (5-year average 10-year Treasury yield 3.87% (spot 5.13% on 2026-10-21)) + β 0.80 after Blume adjustment × 5%, rounded to 0.01% (1bp)
methodology §4.5: market-weighted WACC, not rounded
The model uses the recorded 5-year average Treasury yield. The spot yield is shown for context.
Every input, with its source
Show 159 inputs · reported, guidance and rule-based
| Input | Value | Basis | Why |
|---|---|---|---|
| Revenue FY2026Upstream | $137.0B | Rule | §4.2 target; growth 27.8% corporate.exxonmobil.com ↗ |
| Revenue FY2030Upstream | $135.7B | Guidance | §4.2 target; growth -0.2% corporate.exxonmobil.com ↗ |
| EBIT margin FY2030Upstream | 30.1% | Guidance | §4.3 EBIT 30.1% byFY2030; then held corporate.exxonmobil.com ↗ |
| Capex / revenue FY2026Upstream | 17.7% | Rule | FY1 full-year cash capital budget allocation / gross FY1 revenue, not a server replacement calculation. corporate.exxonmobil.com ↗ · corporate.exxonmobil.com ↗ |
| Reported DD&A / revenueUpstream | 20.2% | Reported | Note 3 segment DD&A plus allocated corporate 1.434B /same gross revenue; see notes. sec.gov ↗ |
| Sustaining capex floor / revenueUpstream | 16.0% | Rule | 90% of lowest funded capex/revenue, maintained forever; full budget is paid. See notes. corporate.exxonmobil.com ↗ |
| Long-run reserve replacementUpstream | 100.0% | Rule | Assume 100% long-run funded reserve renewal; no future free acquisitions. See notes. corporate.exxonmobil.com ↗ |
| Current reserve coverage (not equipment life)Upstream | 10.7 years | Reported | 19.3B proved/1.8B annual reserve production=10.72 years; group diagnostic, not equipment life. sec.gov ↗ |
| Brent USD2030 nominal ($65 in2024 real dollars; 2.5% annual inflation)Upstream | $75.38 | Rule | $65Brent 2024 real dollars, inflated 2.5% for 6 years to 2030; see notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2026Upstream | 17.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2027Upstream | 18.2% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2028Upstream | 18.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2029Upstream | 19.1% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2030Upstream | 19.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2031Upstream | 19.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2032Upstream | 19.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2033Upstream | 19.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2034Upstream | 19.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| After-tax affiliate cash FY2026Upstream | $5.6B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2027Upstream | $5.6B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2028Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2029Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2030Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2031Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2032Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2033Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2034Upstream | $5.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| Terminal growthUpstream | 2.0% | Rule | methodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗ |
| Revenue FY2026Energy Products | $436.3B | Rule | §4.2 target; growth 49.6% corporate.exxonmobil.com ↗ |
| Revenue FY2030Energy Products | $318.1B | Guidance | §4.2 target; growth -7.6% corporate.exxonmobil.com ↗ |
| EBIT margin FY2030Energy Products | 3.8% | Rule | §4.3 EBIT 3.8% byFY2030; then held sec.gov ↗ |
| Capex / revenue FY2026Energy Products | 0.4% | Rule | FY1 full-year cash capital budget allocation / gross FY1 revenue, not a server replacement calculation. corporate.exxonmobil.com ↗ · corporate.exxonmobil.com ↗ |
| Reported DD&A / revenueEnergy Products | 0.9% | Reported | Note 3 segment DD&A plus allocated corporate 1.434B /same gross revenue; see notes. sec.gov ↗ |
| Sustaining capex floor / revenueEnergy Products | 0.4% | Rule | 90% of lowest funded capex/revenue, maintained forever; full budget is paid. See notes. corporate.exxonmobil.com ↗ |
| Long-run reserve replacementEnergy Products | 100.0% | Rule | Assume 100% long-run funded reserve renewal; no future free acquisitions. See notes. corporate.exxonmobil.com ↗ |
| Current reserve coverage (not equipment life)Energy Products | 10.7 years | Reported | 19.3B proved/1.8B annual reserve production=10.72 years; group diagnostic, not equipment life. sec.gov ↗ |
| Brent USD2030 nominal ($65 in2024 real dollars; 2.5% annual inflation)Energy Products | $75.38 | Rule | $65Brent 2024 real dollars, inflated 2.5% for 6 years to 2030; see notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2026Energy Products | 0.4% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2027Energy Products | 0.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2028Energy Products | 0.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2029Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2030Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2031Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2032Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2033Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2034Energy Products | 0.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| After-tax affiliate cash FY2026Energy Products | $0.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2027Energy Products | $0.5B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2028Energy Products | $0.4B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2029Energy Products | $0.4B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2030Energy Products | $0.4B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2031Energy Products | $0.3B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2032Energy Products | $0.3B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2033Energy Products | $0.3B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2034Energy Products | $0.3B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| Terminal growthEnergy Products | 2.0% | Rule | methodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗ |
| Revenue FY2026Chemical Products | $39.8B | Rule | §4.2 target; growth 20.8% corporate.exxonmobil.com ↗ |
| Revenue FY2030Chemical Products | $37.3B | Guidance | §4.2 target; growth -1.6% corporate.exxonmobil.com ↗ |
| EBIT margin FY2030Chemical Products | 2.2% | Rule | §4.3 EBIT 2.2% byFY2030; then held sec.gov ↗ |
| Capex / revenue FY2026Chemical Products | 3.2% | Rule | FY1 full-year cash capital budget allocation / gross FY1 revenue, not a server replacement calculation. corporate.exxonmobil.com ↗ · corporate.exxonmobil.com ↗ |
| Reported DD&A / revenueChemical Products | 4.4% | Reported | Note 3 segment DD&A plus allocated corporate 1.434B /same gross revenue; see notes. sec.gov ↗ |
| Sustaining capex floor / revenueChemical Products | 2.9% | Rule | 90% of lowest funded capex/revenue, maintained forever; full budget is paid. See notes. corporate.exxonmobil.com ↗ |
| Long-run reserve replacementChemical Products | 100.0% | Rule | Assume 100% long-run funded reserve renewal; no future free acquisitions. See notes. corporate.exxonmobil.com ↗ |
| Current reserve coverage (not equipment life)Chemical Products | 10.7 years | Reported | 19.3B proved/1.8B annual reserve production=10.72 years; group diagnostic, not equipment life. sec.gov ↗ |
| Brent USD2030 nominal ($65 in2024 real dollars; 2.5% annual inflation)Chemical Products | $75.38 | Rule | $65Brent 2024 real dollars, inflated 2.5% for 6 years to 2030; see notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2026Chemical Products | 3.2% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2027Chemical Products | 3.3% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2028Chemical Products | 3.4% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2029Chemical Products | 3.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2030Chemical Products | 3.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2031Chemical Products | 3.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2032Chemical Products | 3.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2033Chemical Products | 3.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2034Chemical Products | 3.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| After-tax affiliate cash FY2026Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2027Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2028Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2029Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2030Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2031Chemical Products | $0.8B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2032Chemical Products | $0.7B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2033Chemical Products | $0.7B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2034Chemical Products | $0.7B | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| Terminal growthChemical Products | 2.0% | Rule | methodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗ |
| Revenue FY2026Specialty Products | $23.8B | Rule | §4.2 target; growth 16.4% corporate.exxonmobil.com ↗ |
| Revenue FY2030Specialty Products | $23.1B | Guidance | §4.2 target; growth -0.7% corporate.exxonmobil.com ↗ |
| EBIT margin FY2030Specialty Products | 19.7% | Rule | §4.3 EBIT 19.7% byFY2030; then held sec.gov ↗ |
| Capex / revenue FY2026Specialty Products | 2.4% | Rule | FY1 full-year cash capital budget allocation / gross FY1 revenue, not a server replacement calculation. corporate.exxonmobil.com ↗ · corporate.exxonmobil.com ↗ |
| Reported DD&A / revenueSpecialty Products | 1.6% | Reported | Note 3 segment DD&A plus allocated corporate 1.434B /same gross revenue; see notes. sec.gov ↗ |
| Sustaining capex floor / revenueSpecialty Products | 2.2% | Rule | 90% of lowest funded capex/revenue, maintained forever; full budget is paid. See notes. corporate.exxonmobil.com ↗ |
| Long-run reserve replacementSpecialty Products | 100.0% | Rule | Assume 100% long-run funded reserve renewal; no future free acquisitions. See notes. corporate.exxonmobil.com ↗ |
| Current reserve coverage (not equipment life)Specialty Products | 10.7 years | Reported | 19.3B proved/1.8B annual reserve production=10.72 years; group diagnostic, not equipment life. sec.gov ↗ |
| Brent USD2030 nominal ($65 in2024 real dollars; 2.5% annual inflation)Specialty Products | $75.38 | Rule | $65Brent 2024 real dollars, inflated 2.5% for 6 years to 2030; see notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2026Specialty Products | 2.4% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2027Specialty Products | 2.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2028Specialty Products | 2.5% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2029Specialty Products | 2.6% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2030Specialty Products | 2.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2031Specialty Products | 2.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2032Specialty Products | 2.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2033Specialty Products | 2.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| Capex / revenue FY2034Specialty Products | 2.7% | Rule | Annual cash budget / gross revenue; allocation in notes. corporate.exxonmobil.com ↗ |
| After-tax affiliate cash FY2026Specialty Products | −$52.389M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2027Specialty Products | −$52.016M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2028Specialty Products | −$51.646M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2029Specialty Products | −$51.278M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2030Specialty Products | −$50.913M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2031Specialty Products | −$50.551M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2032Specialty Products | −$50.191M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2033Specialty Products | −$49.834M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| After-tax affiliate cash FY2034Specialty Products | −$49.479M | Rule | After-tax affiliate cash, excluded from EBIT; see notes. sec.gov ↗ |
| Terminal growthSpecialty Products | 2.0% | Rule | methodology §4.2 terminal growth for a mature line Valuation methodology §4.2 · Read methodology ↗ |
| Share of revenue FY2026Company costs | 1.2% | Rule | Annual cost baseline $5.531B; scales with operating revenue; full reconciliation in research sec.gov ↗ |
| Share of revenue FY2034Company costs | 1.2% | Rule | Annual cost baseline $5.531B; scales with operating revenue; full reconciliation in research sec.gov ↗ |
| WACCDiscount rates | 7.54% | Rule | methodology §4.5: market-weighted WACC, not rounded FRED DGS10 2021-10-20..2026-10-21 |
| Cost of equityDiscount rates | 7.87% | Rule | r_f 3.87% (5-year average 10-year Treasury yield 3.87% (spot 5.13% on 2026-10-21)) + β 0.80 after Blume adjustment × 5%, rounded to 0.01% (1bp) 60 monthly returns vs SPY, 2021-09..2026-09 (adjusted closes) |
| Tax rateDiscount rates | 28.0% | Rule | FY2025 cash tax $11.563B / pretax $41.268B = 28.02%, rounded; retained latest-year research proxy. Predecessor history is now restored, but this data-layer repair does not introduce a new tax assumption. sec.gov ↗ |
| Revenue eliminated FY2026Consolidation | $163.7B | Rule | FY2026 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2027Consolidation | $158.1B | Rule | FY2027 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2028Consolidation | $152.8B | Rule | FY2028 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2029Consolidation | $148.0B | Rule | FY2029 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2030Consolidation | $143.5B | Rule | FY2030 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2031Consolidation | $139.3B | Rule | FY2031 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2032Consolidation | $135.4B | Rule | FY2032 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2033Consolidation | $131.8B | Rule | FY2033 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Revenue eliminated FY2034Consolidation | $128.4B | Rule | FY2034 reported internal-sales share at forecast mix. See notes. sec.gov ↗ |
| Profit eliminated FY2026Consolidation | $0.0B | Rule | FY2026 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2027Consolidation | $0.0B | Rule | FY2027 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2028Consolidation | $0.0B | Rule | FY2028 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2029Consolidation | $0.0B | Rule | FY2029 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2030Consolidation | $0.0B | Rule | FY2030 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2031Consolidation | $0.0B | Rule | FY2031 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2032Consolidation | $0.0B | Rule | FY2032 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2033Consolidation | $0.0B | Rule | FY2033 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Profit eliminated FY2034Consolidation | $0.0B | Rule | FY2034 zero net profit: counterpart purchases offset sales. See notes. sec.gov ↗ |
| Corporate revenue display FY2026Consolidation | $1.0B | Rule | FY2026 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2027Consolidation | $1.0B | Rule | FY2027 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2028Consolidation | $1.0B | Rule | FY2028 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2029Consolidation | $1.0B | Rule | FY2029 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2030Consolidation | $1.0B | Rule | FY2030 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2031Consolidation | $1.0B | Rule | FY2031 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2032Consolidation | $1.0B | Rule | FY2032 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2033Consolidation | $1.0B | Rule | FY2033 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| Corporate revenue display FY2034Consolidation | $1.0B | Rule | FY2034 corporate revenue display; earnings already in net costs. See notes. sec.gov ↗ |
| fiscalYearHistorical accounting reconciliation | FY2025 | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| grossRevenueBHistorical accounting reconciliation | $453.2B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| revenueEliminationsBHistorical accounting reconciliation | $121.0B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| consolidatedRevenueBHistorical accounting reconciliation | $332.2B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| segmentProfitBHistorical accounting reconciliation | $46.2B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| profitEliminationsBHistorical accounting reconciliation | $0.0B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| corporateCostsBHistorical accounting reconciliation | $4.3B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| operatingInterestBHistorical accounting reconciliation | $0.6B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| consolidatedPretaxBHistorical accounting reconciliation | $41.3B | Reported | FY2025 Note 3 consolidated reconciliation; full equation in research notes. sec.gov ↗ |
| Cash and short-term investmentsBalance sheet | $10.6B | Reported | cash, cash equivalents and short-term investments us-gaap:CashAndCashEquivalentsAtCarryingValue · 0000034088-26-000093 (filed 2026-08-03) |
| BorrowingsBalance sheet | $42.4B | Reported | borrowings due within a year plus long-term borrowings us-gaap:DebtCurrent · 0000034088-26-000093 + us-gaap:LongTermDebtAndCapitalLeaseObligations · 0000034088-26-000093 |
| Finance leasesBalance sheet | $0.0B | Reported | finance leases not separately tagged; retained inside combined debt, with no additional lease deduction balance sheet 2026-06-30 |
| Minority interestsBalance sheet | $6.7B | Reported | noncontrolling interests at book value us-gaap:MinorityInterest · 0000034088-26-000093 (filed 2026-08-03) |
| SharesBalance sheet | 4.112B | Reported | shares outstanding as of 2026-06-30 cover page of 10-Q 0000034088-26-000093 |
| Dividends per yearShareholders | $16.8B | Reported | Trailing four paid quarters through June 2026 = FY2025 $4.00 - H1 FY2025 $1.98 + H1 FY2026 $2.06 = $4.08. No assumed future buyback share reduction. × 4.112B shares sec.gov ↗ |
Research notes
- unallocated company costs: $5.5B a year (1.7% of trailing revenue), growing with the lines, valued as one negative business
- cost of equity 7.87% (β 0.80 after Blume adjustment), WACC 7.5%
- Energy Products: FY2030 margin set to 3.8% instead of 7.3% (§4.3 E2: 0.5100 points = 4pp × clamp((CAGR − 1.5%) / 2%, 0, 1); revenue CAGR 1.8% to FY2030; no cited expansion evidence)
- Chemical Products: FY2030 margin set to 2.2% instead of 4.2% (§4.3 E2: 2.0000 points = 4pp × clamp((CAGR − 1.5%) / 2%, 0, 1); revenue CAGR 2.5% to FY2030; no cited expansion evidence)
- Specialty Products: FY2030 margin set to 19.7% instead of 21.7% (§4.3 E2: 2.0000 points = 4pp × clamp((CAGR − 1.5%) / 2%, 0, 1); revenue CAGR 2.5% to FY2030; no cited expansion evidence)
- Upstream: Brent USD2030 nominal ($65 in 2024 real dollars; 2.5% annual inflation) $75.38007218383785, DD&A 20.2% of revenue; perpetuity requires 100% reserve replacement and at least 16.0% sustaining capex. Reserves are not equipment lives.
- Energy Products: Brent USD2030 nominal ($65 in 2024 real dollars; 2.5% annual inflation) $75.38007218383785, DD&A 0.9% of revenue; perpetuity requires 100% reserve replacement and at least 0.4% sustaining capex. Reserves are not equipment lives.
- Chemical Products: Brent USD2030 nominal ($65 in 2024 real dollars; 2.5% annual inflation) $75.38007218383785, DD&A 4.4% of revenue; perpetuity requires 100% reserve replacement and at least 2.9% sustaining capex. Reserves are not equipment lives.
- Specialty Products: Brent USD2030 nominal ($65 in 2024 real dollars; 2.5% annual inflation) $75.38007218383785, DD&A 1.6% of revenue; perpetuity requires 100% reserve replacement and at least 2.2% sustaining capex. Reserves are not equipment lives.
Signal Ledger research built from cited consensus, company plans and peer economics because management sets no usable targets — not a forecast and not investment advice. The research desk (GPT-6.1 (Codex)) gathers filings, guidance and targets; deterministic code applies the samepublished rules to every company and checks the result. Inputs may contain errors; follow the source links before relying on them. Read our valuation methodology →